Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM, Liu MC, Chen YH, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC, Lee YL, Lin YL, Shih SR, Huang CG, Liao CC, Liang JJ, Chang CS, Chen C, Lien CE, Tai IC, Lin TY. Hsieh SM, et al. Among authors: lien ce. Lancet Respir Med. 2021 Dec;9(12):1396-1406. doi: 10.1016/S2213-2600(21)00402-1. Epub 2021 Oct 13. Lancet Respir Med. 2021. PMID: 34655522 Free PMC article. Clinical Trial.
Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2.
Huang KA, Zhou D, Tan TK, Chen C, Duyvesteyn HME, Zhao Y, Ginn HM, Qin L, Rijal P, Schimanski L, Donat R, Harding A, Gilbert-Jaramillo J, James W, Tree JA, Buttigieg K, Carroll M, Charlton S, Lien CE, Lin MY, Chen CP, Cheng SH, Chen X, Lin TY, Fry EE, Ren J, Ma C, Townsend AR, Stuart DI. Huang KA, et al. Among authors: lien ce. Theranostics. 2022 Jan 1;12(1):1-17. doi: 10.7150/thno.65563. eCollection 2022. Theranostics. 2022. PMID: 34987630 Free PMC article.
Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
Estephan L, Lin YC, Lin YT, Chen YH, Pan SC, Hsieh SM, Torkehagen PF, Weng YJ, Cheng HY, Estrada JA, Waits A, Chen C, Lien CE. Estephan L, et al. Among authors: lien ce. Vaccine. 2023 May 26;41(23):3497-3505. doi: 10.1016/j.vaccine.2023.04.029. Epub 2023 Apr 12. Vaccine. 2023. PMID: 37080829 Free PMC article. Clinical Trial.
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
Torales J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, Estigarribia G, Sanabria G, Lin MY, Antonio Estrada J, Estephan L, Cheng HY, Chen C, Janssen R, Lien CE. Torales J, et al. Among authors: lien ce. Vaccine. 2023 Jan 4;41(1):109-118. doi: 10.1016/j.vaccine.2022.10.030. Epub 2022 Nov 18. Vaccine. 2023. PMID: 36404171 Free PMC article. Clinical Trial.
21 results